(The Conversation is an independent and nonprofit source of news, analysis and commentary from academic experts.) C. Michael White, University of Connecticut (THE CONVERSATION) A generic blood ...
CEO Narasimhan says no tariff impact on guidance Top-selling heart drug Entresto sees growth stall Older drugs hit by 'generic erosion' in US market Newer drugs help offset some of the slowdown ...
Drugs from Novartis’ oncology segment spurred much of the Q3 growth. Credit: OleksSH via Shutterstock.com. Fast growth for recently label-expanded drugs fuelled Novartis’ Q3 performance, despite ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback